|
|
GPI-0100 |
|
Vaxjo ID |
486 |
|
Vaccine Adjuvant Name |
GPI-0100 |
|
Adjuvant VO ID |
VO_0005763
|
|
Description |
semisynthetic saponin vaccine adjuvant that induces Th1/Th2 balanced response |
|
Stage of Development |
Research |
|
Location Licensed |
United States |
|
Host Species for Testing |
Mouse |
|
Components |
saponins from Quillaja saponaria Molina saponins |
|
Structure |
dodecylamide saponin derivative |
|
Molecular Weight |
1.9 kDa |
|
Preparation |
prepared from Q. saponin extract |
|
Function |
Type: tensoactive compound vaccine adjuvant. Induces Th1/Th2 mixed immune profile. stimulates production of CTLs |
|
Safety |
very low toxicity, less than QS-21 |
| References |
Marciani et al., 2000: Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V, Gundy LE, Farmer JT, Koratich MS, May RD. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 2000; 18(27); 3141-3151. [PubMed: 10856794].
Marciani et al., 2003: Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD. Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine. 2003; 21(25-26); 3961-3971. [PubMed: 12922132].
Wang et al., 2020: Wang P, Ding X, Kim H, Michalek SM, Zhang P. Structural Effect on Adjuvanticity of Saponins. Journal of medicinal chemistry. 2020; 63(6); 3290-3297. [PubMed: 32101001].
|
|
